Marc Willuhn

Marc Willuhn works as the Head of CMC (Chemistry, Manufacturing and Control). Previously, he was VP R&D at Fresenius Kabi and Head of the Innovation & Development Centre in Uppsala, Sweden. Prior to that, he was Director of Process Development at Baxter Healthcare. Earlier in his career, Marc Willuhn worked in chemical development at Schering AG and Sigma-Aldrich. He obtained his PhD in organic chemistry at the Max Planck Institute for Coal Research in Germany and carried out post-doctoral research at the Faculté de Pharmacie in Paris, France. Marc Willuhn owns 25 000 shares in Klaria Pharma.